RSV Vaccine Options: Arexvy, mResvia, Abrysvo for Adults

Understanding RSV: A Serious Threat to Adults

Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for certain adults, particularly those aged 50 and older, RSV can be far more dangerous, leading to severe illness, hospitalization, and even death. It's a significant public health concern, often mistaken for the flu or a common cold, but its impact can be just as debilitating, especially on vulnerable populations. The good news is that advancements in medical science have led to the development of effective RSV Vaccine for Adults: Understanding Risk & Prevention, offering crucial protection.

Unlike the common cold, RSV can inflame the lungs and airways, potentially causing bronchiolitis (inflammation of the small airways in the lungs) and pneumonia. For older adults, particularly those with underlying health conditions, an RSV infection can exacerbate existing chronic diseases, leading to complications like heart attack, congestive heart failure, and severe breathing difficulties. Recognizing the gravity of this virus, health organizations like the CDC have issued clear guidance on vaccination to mitigate these risks.

Who Should Get an RSV Vaccine? Decoding CDC Recommendations

The Centers for Disease Control and Prevention (CDC) provides clear recommendations on who should receive an RSV vaccine to help prevent serious illness and hospitalization. It's not a universal recommendation for all adults, but rather targeted at those most vulnerable.

Age-Based Recommendations

All adults aged 75 and older: This group is universally recommended to receive a single dose of the RSV vaccine due to their naturally weakened immune systems and higher susceptibility to severe outcomes.
Adults aged 50–74 at increased risk of severe RSV illness: For individuals in this age bracket, vaccination is advised if they have certain underlying health conditions that elevate their risk of complications from an RSV infection.

Increased Risk Factors: Beyond Age

Understanding what constitutes "increased risk" is crucial for adults aged 50-74. These conditions can significantly compromise the body's ability to fight off RSV, leading to more severe disease. If you fall into this age group and have any of the following, discussing RSV vaccination with your healthcare provider is highly recommended:

Chronic Cardiovascular Disease: Conditions like heart failure, coronary artery disease, or congenital heart disease (excluding isolated hypertension) can make the heart and lungs more vulnerable to the stress of an RSV infection.
Chronic Lung or Respiratory Disease: Conditions such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, interstitial lung disease, or cystic fibrosis impair lung function, making individuals highly susceptible to severe respiratory infections.
End-Stage Renal Disease or Dependence on Hemodialysis: Kidney disease can weaken the immune system and make the body less resilient to severe infections.
Diabetes Mellitus with Complications: Diabetes complicated by chronic kidney disease, neuropathy, retinopathy, or other end-organ damage, or requiring insulin/SGLT2 inhibitor treatment, indicates a more advanced disease state that increases vulnerability.
Neurologic or Neuromuscular Conditions: Conditions causing impaired airway clearance or respiratory muscle weakness (e.g., post-stroke dysphagia, ALS, muscular dystrophy) can make it difficult to clear secretions and breathe, escalating RSV risks.
Chronic Liver Disease: Conditions like cirrhosis can weaken the immune response.
Chronic Hematologic Conditions: Diseases such as sickle cell disease or thalassemia affect blood health and can impact overall immune function.
Severe Obesity: A body mass index (BMI) of ≥40 kg/m² can restrict lung function and increase inflammation, making respiratory infections more dangerous.
Moderate or Severe Immune Compromise: This includes conditions like HIV/AIDS, cancer (especially during treatment), organ transplant recipients, or those on immunosuppressive medications.
Residence in a Nursing Home: Living in communal settings increases exposure risk, and residents often have multiple underlying health issues.
Other Chronic Medical Conditions or Risk Factors: Healthcare providers may identify other situations, such as frailty or residence in remote areas, where severe RSV disease poses an elevated risk.

For a deeper dive into specific risk factors and who qualifies for the vaccine, you can read our article: Who Needs the RSV Vaccine? CDC Guidance for Adults 50+.

The Three Frontrunners: Arexvy, mResvia, and Abrysvo

As of recent guidance, three FDA-licensed RSV vaccines are recommended for use in adults aged 50 and older: Arexvy, mResvia, and Abrysvo. Each vaccine works by prompting your immune system to produce antibodies that can protect you from severe respiratory disease if you encounter RSV in the future. Importantly, the CDC states there is no preference for which vaccine eligible adults should receive.

Arexvy (GSK)

Manufactured by GlaxoSmithKline (GSK), Arexvy was one of the first RSV vaccines approved for adults 60 and older. It has since expanded its indication. Arexvy is an adjuvanted recombinant subunit vaccine, meaning it uses a specific protein from the RSV virus (the F protein) combined with an adjuvant to boost the immune response. It is administered as a single dose.

mResvia (Moderna)

Moderna's mResvia is a messenger RNA (mRNA) vaccine, similar to their COVID-19 vaccine technology. It delivers genetic instructions to your cells to produce the RSV F protein, triggering an immune response. This single-dose vaccine offers another innovative approach to protection against severe RSV illness for adults 50 and older.

Abrysvo (Pfizer)

Pfizer's Abrysvo is another recombinant subunit vaccine. Like Arexvy, it targets the RSV F protein, but its formulation differs. Abrysvo has the unique distinction of also being approved for pregnant individuals to protect their newborns from RSV, though the focus here is on adult vaccination. For adults 50 and older, it provides a single-dose option for preventing severe RSV disease.

No Preference: Choosing Your Vaccine

Given that all three vaccines are FDA-licensed and recommended by the CDC without preference, the choice often comes down to availability at your pharmacy or doctor's office, or your healthcare provider's specific recommendation based on their practice's stock. The key message is to get vaccinated with any of the available and licensed RSV vaccines if you are eligible, rather than waiting for a specific brand.

Timing Your RSV Vaccination for Optimal Protection

While an RSV vaccine can be administered at any time of year, strategic timing can maximize its protective benefits before the virus typically begins its seasonal spread. The CDC offers clear guidance on when to aim for vaccination:

Best Time: Late Summer and Early Fall: RSV activity usually starts to pick up in communities during the fall and winter months. Getting vaccinated in late summer or early fall allows your body sufficient time to build a robust immune response before RSV circulation intensifies. This pre-season vaccination offers the best chance for protection when you need it most.
Flexibility for Vaccination: If you miss the late summer/early fall window, don't despair. Eligible adults who have not previously received an RSV vaccination can still get vaccinated at any time of the year. Any protection is better than none.

It's important to remember that the RSV vaccine is not currently an annual vaccine. If you have already received one dose of an RSV vaccine (including in previous years), you have completed your vaccination for now and should not receive another dose at this time. Always consult with your healthcare provider to confirm your vaccination status and discuss what is appropriate for you.

Key Takeaways and What's Next for RSV Vaccination

The availability of effective RSV vaccine for adults marks a significant step forward in protecting vulnerable populations from a potentially severe respiratory illness. Understanding the recommendations, vaccine options, and optimal timing is crucial for making informed health decisions.

Here are the essential points to remember:

Targeted Protection: RSV vaccination is recommended for all adults 75 and older, and for adults 50-74 with specific underlying health conditions that increase their risk of severe disease.
Three Trusted Options: Arexvy (GSK), mResvia (Moderna), and Abrysvo (Pfizer) are the FDA-licensed vaccines available, with no preferential recommendation from the CDC.
Single Dose: A single dose completes the current recommended vaccination course. It is not an annual vaccine at this time.
Optimal Timing: Aim for vaccination in late summer or early fall to ensure protection before RSV season begins, though vaccination can occur year-round.

The landscape of vaccine development is continuously evolving. While the RSV vaccine is currently a one-time dose for eligible adults, future research and epidemiological data may lead to updated recommendations. Staying informed through reliable sources like the CDC and regular consultations with your doctor is paramount.

Conclusion

RSV is no longer just a concern for infants; it poses a serious threat to the health of older adults and those with compromised health. With the advent of highly effective vaccines like Arexvy, mResvia, and Abrysvo, eligible adults now have powerful tools to protect themselves against severe RSV illness and its potentially life-altering complications. Don't underestimate the risk of RSV. Take proactive steps, consult with your healthcare provider to assess your eligibility and discuss the best vaccination plan for you. Protecting yourself today means a healthier, more secure tomorrow.